GlobeNewsWire
25 Feb 2026, 21:01 UTC · 34w ago
Impact · against what's priced in
Kiniksa Pharmaceuticals is bullishly positioned following a significant raise in 2026 revenue guidance for ARCALYST and strong Q2 growth. The upward revision of annual revenue expectations to nearly $1 billion indicates stronger market penetration than previously anticipated.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Kiniksa increased the 2026 expected net product revenue for ARCALYST to a range of $980 - $995 million.
So whatRaising full-year revenue guidance is a strong bullish signal indicating higher-than-expected product demand or market penetration.
More positive than 93% of claims this week
ARCALYST generated $243.6 million in Q2 2026 net product revenue, reflecting approximately 55% year-over-year growth.
Continue reading
5 related stories
The company raised its 2026 net product revenue guidance for ARCALYST to $980 - $995 million and reported 55% year-over-year growth in Q2 2026 revenue to $243.6 million.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
Kiniksa management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026.
Near neutral — 98% of claims this week are stronger
Which stocks this story touches
More positive than 89% of ticker scores this week
The company reported significant 55% year-over-year growth for ARCALYST and increased its 2026 revenue guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
39m ago
+112.1%
Price agrees with the score
$90.70 vs $42.76 close before publication (Feb 25) · not market-adjusted
KNSA chart →
